{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T00:40:01Z","timestamp":1749948001757,"version":"3.41.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>There are no definite end-points for stopping therapy in pediatric chronic hepatitis B (CHB). The study objective was to evaluate the incidence of relapse after stopping antiviral therapy and to identify its predictors.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>All hepatitis B surface antigen (HBsAg) positive children presenting to our hospital, who had been on antivirals for at least 2 years with undetectable hepatitis B virus-deoxyribonucleic acid (HBV-DNA) and normal alanine aminotransferase (ALT) on 3 consecutive occasions over last 12 months were included. Antivirals were stopped if liver biopsy showed histological activity index &lt;5 and fibrosis (Ishak) &lt;3. Virological relapse was defined as the elevation of HBV-DNA (&gt;2000 IU\/mL) and biochemical relapse as a rise in ALT levels to &gt;2 times the upper limit of normal. Those having biochemical relapse were started on pegylated interferon alpha-2b-based sequential therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Of the 114 children with CHB screened, 31 HBsAg-positive children fulfilled inclusion criteria and antivirals were stopped in them. Virological and biochemical relapse was seen in 12 (38.7%) and 5 (16.1%) children within 12 months of stopping antiviral treatment. On Cox regression, hepatitis B e antigen (HBeAg) positive status at the time of stopping antiviral therapy (HR: 6.208, 95% CI: 1.630\u201323.638) and longer time taken for HBV-DNA to become undetectable while on antivirals (HR: 1.027, 95% CI: 1.000\u20131.055) were the independent predictors of relapse.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Discontinuation of antiviral treatment in children with CHB resulted in relapse in one-third of the patients. Relapse was frequent in those who were HBeAg-positive at the time of stopping therapy and in those who required longer therapy for HBV-DNA to become undetectable.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000003602","type":"journal-article","created":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T10:08:47Z","timestamp":1655287727000},"page":"714-719","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Incidence and Predictors of Relapse After Stopping Antiviral Therapy in Pediatric Chronic Hepatitis B"],"prefix":"10.1097","volume":"41","author":[{"given":"Piyush","family":"Upadhyay","sequence":"first","affiliation":[{"name":"Department of Pediatric Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6275-7736","authenticated-orcid":false,"given":"Bikrant Bihari","family":"Lal","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vikrant","family":"Sood","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajeev","family":"Khanna","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ekta","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Virology, Institute of Liver and Biliary Sciences, New Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Archana","family":"Rastogi","sequence":"additional","affiliation":[{"name":"Department of Pathology, Institute of Liver and Biliary Sciences, New Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0888-8625","authenticated-orcid":false,"given":"Seema","family":"Alam","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2022,6,7]]},"reference":[{"key":"R1-20250614","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1136\/gutjnl-2017-314904","article-title":"High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B.","volume":"67","author":"Kim","year":"2018","journal-title":"Gut"},{"key":"R2-20250614","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/nrgastro.2013.13","article-title":"Hepatitis: long-term therapy of chronic hepatitis B reverses cirrhosis.","volume":"10","author":"Lok","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R3-20250614","first-page":"1387","article-title":"The significance of spontaneous hepatitis B e antigen seroconversion in childhood: with special emphasis on the clearance of hepatitis B e antigen before 3 years of age.","volume":"22","author":"Chang","year":"1995","journal-title":"Hepatology"},{"key":"R4-20250614","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.jhep.2013.05.016","article-title":"Management of chronic hepatitis B in childhood: ESPGHAN clinical practice guidelines: consensus of an expert panel on behalf of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition.","volume":"59","author":"Sokal","year":"2013","journal-title":"J Hepatol"},{"key":"R6-20250614","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol Int"},{"key":"R7-20250614","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"R8-20250614","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"AASLD guidelines for treatment of chronic hepatitis B.","volume":"63","author":"Terrault","year":"2016","journal-title":"Hepatology"},{"key":"R9-20250614","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.jhep.2014.04.029","article-title":"The role of hepatitis B surface antigen quantification in predicting HBsAg loss and HBV relapse after discontinuation of lamivudine treatment.","volume":"61","author":"Chen","year":"2014","journal-title":"J Hepatol"},{"key":"R10-20250614","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1111\/liv.14606","article-title":"Hepatitis B surface antigen, core-related antigen and HBV RNA: predicting clinical relapse after NA therapy discontinuation.","volume":"40","author":"Kaewdech","year":"2020","journal-title":"Liver Int"},{"key":"R11-20250614","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/hep.28015","article-title":"Randomized, controlled trial of entecavir versus placebo in children with hepatitis B envelope antigen-positive chronic hepatitis B.","volume":"63","author":"Jonas","year":"2016","journal-title":"Hepatology"},{"key":"R12-20250614","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1002\/hep.25818","article-title":"Randomized, placebo-controlled trial of tenofovir disoproxil fumarate in adolescents with chronic hepatitis B.","volume":"56","author":"Murray","year":"2012","journal-title":"Hepatology"},{"key":"R13-20250614","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/hep.28278","article-title":"Antiviral therapy in management of chronic hepatitis B viral infection in children: a systematic review and meta-analysis.","volume":"63","author":"Jonas","year":"2016","journal-title":"Hepatology"},{"key":"R14-20250614","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/s12664-018-0878-1","article-title":"Pegylated interferon-based sequential therapy for treatment of HBeAg reactive pediatric chronic hepatitis B-First study in children.","volume":"37","author":"Lal","year":"2018","journal-title":"Indian J Gastroenterol"},{"key":"R15-20250614","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1053\/j.gastro.2009.12.052","article-title":"SAFETY study: alanine aminotransferase cutoff values are set too high for reliable detection of pediatric chronic liver disease.","volume":"138","author":"Schwimmer","year":"2010","journal-title":"Gastroenterology"},{"key":"R16-20250614","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/0168-8278(95)80226-6","article-title":"Histological grading and staging of chronic hepatitis.","volume":"22","author":"Ishak","year":"1995","journal-title":"J Hepatol"},{"key":"R17-20250614","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1002\/jmv.21477","article-title":"Validation of a sensitive and specific real-time PCR for detection and quantitation of hepatitis B virus covalently closed circular DNA in plasma of chronic hepatitis B patients.","volume":"81","author":"Takkenberg","year":"2009","journal-title":"J Med Virol"},{"key":"R18-20250614","doi-asserted-by":"crossref","first-page":"150","DOI":"10.4103\/0255-0857.96664","article-title":"Serum hepatitis B surface antigen levels correlate with high serum HBV DNA levels in patients with chronic hepatitis B: a cross-sectional study.","volume":"30","author":"Gupta","year":"2012","journal-title":"Indian J Med Microbiol"},{"key":"R19-20250614","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s12072-021-10223-5","article-title":"APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients.","volume":"15","author":"Kao","year":"2021","journal-title":"Hepatol Int"},{"key":"R20-20250614","doi-asserted-by":"crossref","first-page":"e892","DOI":"10.1093\/cid\/ciab007","article-title":"Improving the prediction of relapse after nucleos(t)ide analogue discontinuation in patients with chronic hepatitis B.","volume":"73","author":"Song","year":"2021","journal-title":"Clin Infect Dis"},{"key":"R21-20250614","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ijid.2019.07.036","article-title":"Predictors of relapse after cessation of nucleos(t)ide analog treatment in HBeAg-negative chronic hepatitis B patients: a meta-analysis.","volume":"86","author":"Liu","year":"2019","journal-title":"Int J Infect Dis"},{"key":"R22-20250614","doi-asserted-by":"crossref","first-page":"104992","DOI":"10.1016\/j.antiviral.2020.104992","article-title":"Perspectives on stopping nucleos(t)ide analogues therapy in patients with chronic hepatitis B.","volume":"185","author":"Tout","year":"2021","journal-title":"Antiviral Res"},{"key":"R23-20250614","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1111\/apt.13150","article-title":"Reduced risk of relapse after long-term nucleos(t)ide analogue consolidation therapy for chronic hepatitis B.","volume":"41","author":"Chi","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"R24-20250614","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1002\/hep.26549","article-title":"Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients.","volume":"58","author":"Jeng","year":"2013","journal-title":"Hepatology"},{"key":"R25-20250614","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1002\/hep.28438","article-title":"Discontinuation of oral antivirals in chronic hepatitis B: a systematic review.","volume":"63","author":"Papatheodoridis","year":"2016","journal-title":"Hepatology"},{"key":"R26-20250614","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/hep.29640","article-title":"Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B.","volume":"68","author":"Jeng","year":"2018","journal-title":"Hepatology"},{"key":"R27-20250614","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/apt.15053","article-title":"Hepatitis B virus relapse rates in chronic hepatitis B patients who discontinue either entecavir or tenofovir.","volume":"49","author":"Kuo","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"R28-20250614","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1016\/j.cgh.2020.04.037","article-title":"Incidence and factors associated with HBV relapse after cessation of entecavir or tenofovir in patients with HBsAg below 100 IU\/mL.","volume":"18","author":"Tseng","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R29-20250614","doi-asserted-by":"crossref","first-page":"4967","DOI":"10.2147\/IJGM.S321253","article-title":"Hepatitis B core-related antigen is a biomarker for off-treatment relapse after long-term nucleos(t)ide analog therapy in patients with chronic hepatitis B.","volume":"14","author":"Liao","year":"2021","journal-title":"Int J Gen Med"},{"key":"R30-20250614","doi-asserted-by":"crossref","first-page":"100112","DOI":"10.1016\/j.jhepr.2020.100112","article-title":"Rebound of HBV DNA after cessation of nucleos\/tide analogues in chronic hepatitis B patients with undetectable covalently closed.","volume":"2","author":"Lai","year":"2020","journal-title":"JHEP Rep"},{"key":"R31-20250614","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1093\/infdis\/jiaa136","article-title":"Combining hepatitis B virus RNA and hepatitis B core-related antigen: guidance for safely stopping nucleos(t)ide analogues in hepatitis B e antigen-positive patients with chronic hepatitis B.","volume":"222","author":"Fan","year":"2020","journal-title":"J Infect Dis"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000003602","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T00:10:07Z","timestamp":1749946207000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000003602"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,7]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000003602","relation":{},"ISSN":["0891-3668"],"issn-type":[{"type":"print","value":"0891-3668"}],"subject":[],"published":{"date-parts":[[2022,6,7]]}}}